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INTRODUCTION
Immune	mediated	hemolytic	anemia	(IMHA)	
is	 one	 of	 the	 most	 common	 immune	 mediated	
diseases	 in	 dogs.	 The	 most	 commonly	 affected	
individuals	 are	 middle-aged	 female	 dogs.	 Some	
breed	 predispositions	 are	 also	 known,	 with	 the	
Cocker	Spaniel	 being	one	of	 the	most	 commonly	
inflicted	(Balch	and	Mackin,	2007).
Hemolysis	 can	 be	 intravascular	 or	
extravascular	 (in	 the	 liver	 or	 spleen),	 with	 the	
immunopathological	 process	 being	 the	 same	 in	
both	 cases.	 Erythrocytes	 are	marked	 as	 non-self	
by	 the	attachment	of	 IgG	and	 IgM	and	destroyed	
by	 macrophages.	 Red	 blood	 cell	 exrtavascular	
destruction	 occures	 in	 the	 liver,	 but	 mostly	 in	
the	 spleen	 and	 is	 mediated	 by	 IgG,	 whereas	
intravascular	hemolysis	is	mainly	mediated	by	IgM	
(Piek	et al.,	2009).	The	degree	of	autoagglutination	
and	 spherocytosis	 is	 higher	 when	 both	
immunoglobuline	 isotypes	 are	 involved	 (Harkin	
et al., 2012).	This	mechanism	can	be	 initiated	by	
a	 variety	 of	 triggers	 such	 as	 vaccines,	 neoplasia,	
certain	medication,	 infectious	diseases	and	other	
immune	 mediated	 illnesses.	 In	 this	 case	 the	
hemolytic	 anemia	 is	 secondary	 to	 an	 underlying	
disease	process	or	an	administered	substance.	
Primary	immune	mediated	hemolytic	anemia	
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Abstract
Immune	mediated	hemolytic	anemia	(IMHA)	is	a	disease	in	which	the	body’s	own	immune	system	attacks	and	
destroys	the	erythrocytes	causing	anemia.	This	may	be	primary	or	secondary	as	the	result	of	an	underlying	illness	
such	as	neoplasia	or	intracellular	parasites	like	babesiosis.	In	most	cases	the	underlying	trigger	of	the	anemia	may	
never	be	found,	in	which	case	the	disease	is	called	idiopathic	immune-mediated	anemia.	
A	 double	 immunosuppressive	 therapy	 including	 prednisolone	 and	 cyclosporine	 as	 well	 as	 various	 blood	
transfusions	has	been	administered	to	the	patient,	without	any	results.	Mycophenolate	mofetil	was	introduced	as	
the	third	immunosuppressive	drug	on	the	eight	day	after	admission	(Park	et al.,	2012;	Wang	et al,	2013;	West	et 
al,	2014)	
The	diagnosis	of	immune-mediated	hemolytic	anemia	has	been	made	after	the	autoagglutination	test	of	the	
patient	was	positive	after	three	RBC	washes	and	negative	results	for	Ehrlichia, Babesia, Leishmania and Borrelia 
antibodies.	Also,	tumors	have	not	been	found.	The	patient	received in	the	first	eight	days	of	treatment	four	type	
specific	blood	transfusions	with	erythrocyte	concentrate	and	two	immunosuppressive	drugs,	but	still	manifested	
post-transfusion	reactions	after	each	transfusion	with	the	hematocrit	(Hct)	dropping	back	to	 initial	 levels	after	
two	days.	After	the	addition	of	mycophenolate	mofetil	the	Hct	stayed	stable	at	a	higher	level	and	the	patient	was	
discharged	two	weeks	after	with	a	stable	Hct	of	27%.
Mycophenolate	mofetil	can	be	used	in	severe	cases	of	IMHA	when	other	immunosuppressive	agents	might	not	
be	enough.	However	due	to	the	frequently	encountered	side	effects	it	is	recommended	to	be	used	mostly	as	a	last	
resort	therapeutic	agent.		
Keywords: blood transfusion, IMHA, immunosuppressive therapy, mycopphenolat mophetil, prednisolone.
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is	one	of	the	most	common	forms	of	the	disease,	
where	the	triggering	factor	is	unknown	(Piek	et al.,	
2009).
MATERIALS AND METHODS
A	nine	year	old	neutered	female	mixed	breed	
dog	was	presented	to	the	emergency	service	in	the	
Small	Animal	Internal	Medicine	department	of	the	
Justus-Liebig	University	 in	Giessen	with	 lethargy,	
inapetence	and	oligodipsy.	The	symptoms	started	4	
days	earlier	with	lethargy,	weakness	and	vomiting.	
A	 foreign	 object	 or	 poison	 ingestion	 could	 not	
be	 excluded	 by	 the	 owner.	 From	 the	 start	 of	 the	
symptoms	 the	 patient	 was	 treated	 in	 a	 private	
practice	with	antipyretic,	antiemetic	and	antibiotic	
(Metamizol,	 Emeprid,	 Cerenia	 and	 Enrofloxacin)	
medication,	 without	 any	 clinical	 improvement.	
Hematologic	 and	 biochemical	 findings	 included:	
WBC	 6.7	 G/l,	 RBC	 2.0	 T/l,	 Hb	 5.0	 g/l,	 Hct	 17%,	
absolute	reticulocyte	count	89.400	MCV	84	fl,	PLT	
369	G/l,	total	bilirubin	3.4mg/dl,	total	proteins	6.2	
g/dl	and	LDH	226	U/l.	The	blood	smear	showed	
a	 slight	 anisocytosis	 and	 polychromasia.	 Due	 to	
these	 findings,	on	 the	day	before	presentation	 in	
the	clinic	the	patient	received	a	blood	transfusion	
from	 an	 unknown	 donor	 that	 did	 not	 have	 any	
positive	effects.	
In	 the	 clinical	 examination	 the	 dog	 was	
anxious but	 cooperant,	 with	 a	 good	 general	
condition,	pale	and	dry	mucous	membranes	with	a	
capillary	refill	time	less	than	2	seconds.	The	pulse	
was	regular	and	symmetric	of	medium	speed	and	
strength.	Pulse	rate	was	120/minute,	respiratory	
rate	 24/minute	 and	 rectal	 temperature	 39.3	 C0.	
A	 2x3x2	 cm	 large	 mammary	 tumor	 has	 been	
found	on	the	left	cranial	mammary	complex.	The	
thorax	and	abdomen	were	normal	in	the	physical	
examination	 and	 radiographic	 imaging.	 Given	
the	medical	 history	 of	 vomiting	 unresponsive	 to	
treatment,	an	ultrasound	of	the	abdomen	has	been	
performed.	 Except	 for	 a	 slightly	 enlarged	 spleen	
and	gall	bladder	nothing	has	been	found.	
A	quick	hematological	as	well	as	a	blood-gas	
analysis	 and	 blood	 smear	 has	 been	 done	 in	 the	
intensive	care	unit	of	the	clinic	with	the	following	
results:	RBC	2.03	T/l,	Hct	14.8%,	Hb	4.3	mmol/l,	
MCV	 72.9	 fl,	 absolute	 reticulocyte	 count	 171.1	
G/l,	 reticulocyte	 percentage	 8.4	 %,	 WBC	 32.03	
G/l,	 Neutrophiles	 19.92	 M/l,	 Lymphocytes	 6.38	
M/l,	Monocytes	5.67	M/l	and	PLT	156	G/l.	Blood-
gas	 analysis	 results	 were	 all	 within	 reference	
range.	 On	 the	 blood	 smear	 an	 anisocytosis	 and	
polychromasia	with	10-15%	spherocytes	and	15-
20%	 toxic	 band	 neutriphiles	 were	 observed.	 An	
autoagglutination	 test	was	performed	before	 the	
blood	 transfusion,	 which	 resulted	 in	 a	 positive	
reaction	 even	 after	 the	 third	 erythrocyte	 wash.	
Together	with	the	spherocytosis	seen	on	the	blood	
smear	a	preliminary	diagnosis	of	immune	mediated	
hemolytic	 anemia	 has	 been	made	 (Harkin	 et al., 
2012;	Hodges	and	Christopher,	2011).
The	 patient	 received	 a	 type	 specific	 blood	
transfusion	 of	 erythrocyte	 concentrate	 in	
addition	to	the	antithrombotic,	anti-inflammatory	
and	 gastro-intestinal	 protection	 therapy.	
Immunosuppressive	 therapy	 was	 started	 with	
3.6	 mg/kg	 prednisolone.	 During	 the	 transfusion	
the	 patient	 developed	 hyperthermia,	 a	 painful	
abdomen	and	vomiting.	Hematocrit	6	hours	post-
transfusion	 was	 19%	 and	 the	 patient	 improved	
clinically	but	developed	hematuria.	An	abdominal	
ultrasound	showed	signs	of	cholecystitis,	enteritis	
and	blood	cloths	in	the	urinary	bladder.	
From	 the	 third	 day	 after	 admission	 the	
prednisolone	 dose	 was	 reduced	 to	 2	 mg/kg,	
but	 the	 next	 day	 the	 patient’s	 clinical	 state	
deteriorated	with	 RBC	 dropping	 to	 1.41	 T/l	 and	
the	Hct	to	12%.	A	blood	transfusion	of	270	ml	type	
specific	erythrocyte	concentrate	and	cyclosporine	
as	 a	 second	 immunosuppressive	 medicine	 has	
been	started	at	a	dose	of	5.3	mg/kg.	Transfusion	
reactions	have	been	observed	this	time	as	well	and	
8	 hours	 post-transfusion	 the	 patient	 developed	
signs	 of	 hemolysis,	 but	 improved	 clinically.	 The	
Hct	 and	 RBC	 remained	 at	 pre-transfusion	 levels.	
Another	 type	 specific	 erythrocyte	 concentrate	
was	given	that	raised	the	Hct	to	22%	6	hours	after	
transfusion.	
Three	 days	 after	 the	 last	 transfusion	 RBC	
dropped	 to	1.18	T/l	 and	Hct	 to	12%	making	 the	
administration	of	another	type	specific	erythrocyte	
concentrate	necessary.	Post-transfusion	reactions	
haven’t	been	as	 strong	 this	 time,	but	 the	disease	
progression	 justified	 the	 introduction	 of	 a	 third	
immunosuppressive	drug	(Wang	et al.,	2014;	Park	
et al.,	2012).	From	the	eighth	day	after	admission	
mycophenolat	 mofetil	 has	 been	 added	 to	 the	
treatment	protocol	in	a	dose	of	10	mg/kg.	
After	 the	 initiation	 of	 the	 triple	
immunosuppressive	therapy,	the	patient	improved	
every	day	clinically,	it’s	appetite	came	back,	urine	
and	stool	were	normal.	Hematocrit	and	RBC	levels	
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rose	 slowly	 over	 the	 next	 week.	 As	 the	 patients	
gastro-intestinal	 symptoms	 ceased,	 the	 therapy	
was	changed	to	oral	administration.
	Due	to	the	progressive	clinical	improvement	
and	stable	hematological	parameters,	 the	patient	
was	discharged	after	18	days	with	a	Hct	of	27%.	
The	 triple	 immunosuppressive	 therapy,	 along	
with	 the	 antithrombotic	 and	 gastrointestinal	
protective	medication	was	given	for	another	week	
as	an	outpatient	treatment,	until	the	next	control	
examination.
RESULTS AND DISCUSSIONS
Canine	 IMHA	 patients	 often	 require	 the	 use	
of	more	than	one	immunosuppressive	medication	
as	 treatment	 can	 last	 for	 several	 months	 and	
combination	 of	 these	drugs	 allows	 the	physician	
to	use	a	lower	dose	of	each	one,	thus	reducing	the	
side-effects	(Whitley	and	Day,	2011).	
Still,	 a	 triple	 immunosuppressive	 therapy	 is	
used	quite	rarely	 in	veterinary	medicine,	but	 the	
severity	 of	 the	 hemolysis	 in	 this	 particular	 case	
and	 the	 frequent	 relapses	 to	 a	 critical	 state	 of	
the	patient,	 justified	the	usage	of	all	 three	drugs.	
Treatment	has	been	initiated	with	a	glucocorticoid	
drug	with	 the	 later	 addition	 of	 cyclosporine	 and	
mycophenolate	mofetil,	to	the	treatment	protocol	
until	the	desired	effect	has	been	reached	(Tab.	).
The	 patient	 was	 closely	 monitored	 after	
discharge,	 with	 follow-up	 hematological	 tests	
every	 2	 weeks.	 At	 the	 time	 of	 the	 first	 follow–
up	 control	 the	 patient	 has	 been	 under	 a	 triple	
immunosuppressive	 therapy	 for	 24	 days.	
Hematological	 parameters	 showed	 a	 very	 good	
recovery	 with	 RBC	 at	 4.74	 T/l,	 Hct	 38%	 and	
spherocytosis	bellow	4%.	Due	to	this	evolution	the	
prednisolone	dose	has	been	reduced	by	25%	and	
mycofenolat	 mofetil	 was	 taken	 out	 entirely.	 The	
first	two	follow-up	examinations	were	conducted	
at	 2	 weeks	 apart,	 after	 which	 the	 patient	 was	
called	in	every	4	weeks	for	the	following	3	months.	
The	 owner	 reported	 severe	 glucocorticoid	
induced	 side-effects	 on	 the	 first	 follow-up	 visit,	
manifested	thru	massive	polyuria/polydipsia	and	
polyphagia.	
Hematologic	 parameters	 steadily	 increased	
at	each	 follow-up	control,	allowing	the	reduction	
by	 25%	 of	 the	 prednisolone	 dose.	 Side-effects	
produced	by	the	glucocorticoid	medication	slowly	
reduced	as	the	dose	was	lowered.
	 On	 the	 last	 recorded	 visit	 the	 patient’s	
hematological	 parameters	 were	 all	 within	
normal	 reference	 range,	 RBC	 6.11	 T/l,	 Hct	 40%	
and	 spherocytosis	 0%.	 The	 immunosuppressive	
therapy	 has	 been	 reduced	 at	 this	 point	 to	 0.5	
mg/kg	 prednisolone	 and	 cyclosporine	 remained	
unchanged	at	5.3	mg/kg	(Tab.	2)	
Further	 follow-up	 examinations	 were	 done	
in	 a	 private	 practice	 from	 which	 the	 only	 feed-
back	 given	 was	 that	 the	 patient	 is	 doing	 very	
well	 clinically,	 the	 hematologic	 parameters	 are	
within	 normal	 reference	 range	 and	 any	 signs	 of	
glucocorticoid	induced	side-effects	have	ceased.
Mycofenolate	mofetil	is	an	immunosuppressive	
medication	 used	 mostly	 in	 human	 medicine	 on	
transplant	 patients.	 The	 immunomodulating	
effect	 of	 the	 drug	 consists	 in	 the	 prevention	 of	
T	 and	 B	 cell	 proliferation	 and	 differentiation	 by	
reversible	 inhibition	of	the	key	enzyme	in	the	de	
novo	synthesis	of	purine	(Whitley	and	Day,	2011).	
Side	 effects	 of	 the	 medication	 include	 mostly	
gastro-intestinal	symptoms.	
Published	 data	 on	 the	 use	 of	 mycofenolate	
mofetil	 in	 veterinary	 medicine	 is	 contradictory,	
some	 authors	 reporting	 severe	 gastrointestinal	
symptoms	 in	 canine	 patients	 that	 had	 to	 lead	
Tab. 1.	 RBC,	 Hct	 and	 spherocytosis	 evolution	 under	 the	 immunosuppressive	 therapy	 during	
hospitalization	 
Hematological	
parameters
3.6	mg/kg	prednisolone	
2	mg/kg	prednisolone	+
5.3	mg/kg	cyclosporine
2	mg/kg	prednisolone	+
5.3	mg/kg	cyclosporine	+
10	mg/kg	mycofenolat	mofetil
Day	1 Day	2 Day	3 Day	7 Day	10 Day	15
RBC	(T/l) 2.03 2.66 1.41 1.18 1.86 2.73
Hct	(%) 14.8 19 12 12 19 27
Spherocytosis	(%) 5-10 40-50 4 5-10 5-10 <5
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to	 the	 drugs	 discontinuation	 from	 the	 therapy	
(West	 and	 Hart,	 2014),	 while	 other	 researchers	
encountered	no	or	very	mild	side-effects	and	very	
good	therapeutic	results.	(Wang	et al.,	2013,	Park	
et al.,	2012)
In	 this	 particular	 case	 clinical	 and	
hematological	 improvement	 of	 the	 patient	 has	
been	 observed	 only	 after	 the	 introduction	 of	
mycofenolate	mofetil	 in	 the	therapeutic	protocol.	
Severe	 hemolysis	 has	 been	 observed	 with	 the	
use	for	the	first	three	days	of	treatment	with	only	
prednisolone	 in	 an	 immunosuppressive	 dose	 of	
3.6	mg/kg	 as	well	 as	 the	 following	 5	 days	when	
cyclosporine	was	also	added.	
The	 patient	was	 already	manifesting	 gastro-
intestinal	 symptoms	 on	 the	 day	 of	 presentation.	
These	 were	 later	 attributed	 to	 the	 enteritis	
and	 cholecystitis	 suspected	 in	 the	 abdominal	
ultrasound	 examination.	 The	 gastro-intestinal	
symptoms	 persisted	 though	 the	 first	 eight	 days	
of	hospitalization	and	began	to	fade	only	after	the	
overall	 clinical	 improvement	 and	 stabilization	 of	
the	 hematological	 parameters	 of	 the	 patient	 on	
the	triple	immunosuppressive	treatment	protocol.	
CONCLUSIONS 
Immune	mediated	hemolytic	anemia	 in	dogs	
is	 a	 difficult	 to	 treat	 disease	 that	 may	 require	
the	 usage	 of	 multiple	 immunosuppressive	
medications.	 The	 patient	 required	 multiple	
blood	 transfusions	 during	 its	 hospital	 stay	 and	
although	every	erythrocyte	concentrate	has	been	
type	 specific,	 it	 triggered	 immediate	 transfusion	
reactions.	 Setbacks	 in	 form	 of	 hemolysis	 were	
observed	 after	 every	 blood	 transfusion,	 except	
the	 last	one,	when	 the	 third	 immunosuppressive	
medication,	 mycofenolate	 mofetil	 has	 been	
introduced.	
The	patient	did	not	show	any	symptoms	that	
could	 have	 been	 related	 to	 the	 potential	 toxic	
effects	of	mycofenolate	mofetil	manifested	mostly	
through	 gastro-intestinal	 symptoms.	 Given	 the	
fact	that	the	patient	had	a	colecystitis	and	enteritis	
diagnosed	 via	 ultrasound,	 these	 did	 not	 worsen	
after	the	addition	of	the	mycofenolate	mofetil.	
Clinical	 as	 well	 as	 hematological	 parameter	
improvement	 and	 stabilization	 occurred	 in	 a	
relatively	 short	 time,	 the	 patient	 recovered	 well	
enough	 to	 be	 released	 after	 10	 days	 on	 a	 triple	
immunosuppressive	treatment.	
Glucocorticoid	induced	symptoms	represented	
by	 polyuria/polydipsia	 and	 polyphagia	 persisted	
for	 another	 86	 days	 after	 discharge,	 when	 the	
prednisolone	 dose	 could	 be	 safely	 reduced	 to	
less	 than	 1	 mg/kg.	 Severity	 of	 these	 symptoms	
gradually	 reduced	 as	 the	 prednisolone	 dose	 has	
been	steadily	lowered.			
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